Market data loadingS&P 500--NASDAQ--Data as of latest ETNo timestamp
Start free

InnovAge Holding Corp. (INNV) SEC Filings & Earnings Calls

EquiReason read 10 InnovAge Holding Corp. SEC filings in the last 12 months. Latest: DEF 14A on 2026-10-22 — Annual proxy statement filed for shareholder vote on director elections, say-on-pay, and auditor ratification..

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

INNVInnovAge Holding Corp.Follow INNV — free
Medical Care Facilities · Healthcare
—
Price chart with a free account
Market cap
1.3B
P/E TTM
—
Dividend yield
—
52-week
—
Next earnings
3 Nov, in 9 days

Every filing, read

last 12 months · SEC

What happened, the numbers inside, guidance and risks. The original is one click away.

22 Oct 2026DEF 14AAnnual proxy statement filed for shareholder vote on director elections, say-on-pay, and auditor ratification.open

Figures in the filing · each found in the filing text

Net Income (Loss) · FY2026$-683000.00-98% y/y
Total Shareholder Return (based on $100 investment) · FY2026$321.14+311% y/y
Compensation Actually Paid to PEO · FY2026$26M+2612% y/y
Average Compensation Actually Paid to Non-PEO NEOs · FY2026$8M+881% y/y
Principal Shareholders Ownership · 2026-10-1275.2%
Shares Sold in Secondary Offering · 2026-0911,500,000

Risks flagged

Concentrated ownership by Principal Shareholders

“TCO Group Holdings, L.P. 102,576,555 shares 75.2%”

Controlled company with reduced governance protections

“We are a 'controlled company' under the listing standards of Nasdaq.” · word for word

Continued net losses

“Net Income (Loss) ($ in thousands) 2026: $(683)”
Read the original on SEC EDGAR ↗
24 Sep 20268-K · 8.01InnovAge Holding Corp. disclosed a secondary offering of 10M shares by a selling shareholder at $9.25/share; company receives no proceeds.open

Figures in the filing · each found in the filing text

Shares offered · Q3-202610,000,000
Offering price per share · Q3-2026$9.25
Option shares · Q3-20261,500,000

Risks flagged

Secondary offering may signal selling shareholder's desire to exit, potentially pressuring stock price.

“Selling shareholder sold 10M shares; company receives no proceeds.”
Read the original on SEC EDGAR ↗
9 Sep 202610-KInnovAge reported FY2026 results with revenue growth of 15.9% but a net loss of $2.5 million, impacted by $57 million in litigation costs.earningsopen

Figures in the filing · each found in the filing text

Capitation revenue · FY2026$988M+16% y/y
Total revenues · FY2026$990M+16% y/y
External provider costs · FY2026$450M+4% y/y
Cost of care, excluding depreciation and amortization · FY2026$312M+16% y/y
Sales and marketing · FY2026$34M+22% y/y
Corporate, general and administrative · FY2026$166M+36% y/y
Depreciation and amortization · FY2026$21M+8% y/y
Operating Income (Loss) · FY2026$3M
Net Loss Attributable to InnovAge Holding Corp. · FY2026$-3M
Participant census · FY20268,230+6% y/y

Guidance

Anticipated decrease in Colorado Medicaid premium rates retroactive to July 1, 2026; expects rate pressures to impact margins in FY2027

Management expects margin pressure in FY2027 due to Medicaid rate decreases in Colorado and potential rate pressures from other states, partially offset by clinical and operational value initiatives.

Risks flagged

DOJ False Claims Act Investigation

“During fiscal year 2026, we incurred approximately $57.0 million in litigation costs and settlements, including an approximately $37.0 million accrual as of June 30, 2026, substantially all of which is related to the 2021 and 2022 civil investigative demands described above.” · word for word

Medicaid Funding Reduction

“The Reconciliation Act mandated significant reductions in federal Medicaid spending, with the Congressional Budget Office estimating a decrease of $1 trillion over the next decade.” · word for word

Colorado Medicaid Rate Decrease

“In Colorado, where we serve the largest cohort of our PACE census, we anticipate a decrease in Medicaid premium rates which will be retroactive for the fiscal year beginning July 1, 2026.” · word for word

California Expansion Constraint

“Effective November 20, 2025, the California Department of Health Care Services (DHCS) paused PACE applications for all new PACE centers for a minimum of two years” · word for word

PACE Risk Adjustment Model Transition

“Effective January 1, 2026, CMS began phasing in the V28 model with full implementation expected in calendar year 2028.” · word for word
Read the original on SEC EDGAR ↗
8 Sep 20268-K · 2.02InnovAge reported strong FY2026 results: revenue +15.9% to $989.7M, Adj. EBITDA +174% to $94.6M, net loss narrowed 98%. FY2027 guidance implies continued growth with census 8,625-8,850 and revenue $1.05-1.085B.earningsopen

Figures in the filing · each found in the filing text

Total revenues · FY2026$990M+16% y/y
Adjusted EBITDA · FY2026$95M+174% y/y
Census · FY20268,230+6% y/y
Member months · FY202696,050+8% y/y
Center-level Contribution Margin · FY2026$228M+48% y/y
Net Income (Loss) per share - basic and diluted · FY2026$-0.02+91% y/y

Guidance

FY2027 revenue guidance $1.05-1.085B vs FY2026 actual $989.7M; Adj. EBITDA $105-115M vs $94.6M

FY2027 guidance implies continued revenue growth (~8% at midpoint) and margin expansion (Adj. EBITDA margin ~10.5% vs 9.6%).

Risks flagged

Dependence on government payor (Medicare/Medicaid) reimbursement rates; regulatory changes could impact revenue.

“PACE model relies on government funding; not explicitly discussed but inherent risk.”

Concentration in frail senior population; any adverse health event or pandemic could disrupt operations.

“Business model focused on high-cost, frail seniors; not mentioned in filing.”
Read the original on SEC EDGAR ↗
8 May 202610-QQ3 FY2026 results: revenue +15.5% YoY, but operating loss widened to $29.1M due to $51.9M litigation accrual; adjusted EBITDA improved significantly.earningsopen

Figures in the filing · each found in the filing text

Census · PACE · Q3-20268,050+7% y/y
Total Member Months · PACE · 9M-202671,530+8% y/y
Center-level Contribution Margin · PACE · 9M-2026$165M+47% y/y
Center-level Contribution Margin as a % of revenue · PACE · 9M-202622.7%
Adjusted EBITDA · 9M-2026$70M+204% y/y
Adjusted EBITDA Margin · 9M-20269.7%
Revenue · Q3-2026$252M+16% y/y
Net Loss · Q3-2026$-30M-169% y/y
Operating Cash Flow · 9M-2026$43M+82% y/y
Free Cash Flow · 9M-2026$36M+107% y/y

Guidance

Reduced Medicaid premium rate increases expected in Colorado from July 2026; California rate impact from Jan 2027

Revenue growth continues, but margin outlook pressured by Medicaid rate headwinds and litigation costs.

Risks flagged

Litigation Overhang

“Litigation costs and settlement (b) 51,859 ... 54,117” · word for word

Medicaid Rate Pressure

“In Colorado, where we serve the largest cohort of our PACE census, we anticipate reduced Medicaid premium rate increases for the fiscal year beginning July 1, 2026.” · word for word

California Expansion Blocked

“Effective November 20, 2025, the California Department of Health Care Services (DHCS) paused PACE applications for all PACE organizations for a minimum of two years, or until otherwise notified.” · word for word

Labor Cost Inflation

“These labor market pressures have increased wage and benefit costs, and have also affected our staffing ability which could impact our enrollment capacity and services.” · word for word
Read the original on SEC EDGAR ↗
5 May 20268-K · 2.02InnovAge raises FY2026 revenue guidance to $950-975M from prior (not stated) and Adjusted EBITDA to $85-90M; Q3 FY2026 revenue $251.9M (+15.5% YoY); Adjusted EBITDA $30.5M (+182.7% YoY); census 8,050 (+6.9% YoY); net loss widened to $29.9Mopen

Figures in the filing · each found in the filing text

Total revenues · Q3-2026$252M+15% y/y
Adjusted EBITDA · Q3-2026$30M+183% y/y
Center-level Contribution Margin · Q3-2026$61M+50% y/y
Census · Q3-20268,050+7% y/y
Net loss · Q3-2026$-30M+169% y/y
Net loss per share · Q3-2026$-0.22+175% y/y
Cash and cash equivalents · Q3-2026$96M
Total debt · Q3-2026$69M

Guidance

FY2026 total revenues raised to $950-975M; Adjusted EBITDA raised to $85-90M; Census unchanged at 7,900-8,100; Total Member Months unchanged at 92,900-95,700.

Guidance raise driven by stronger operational performance and investment benefits; revenue and EBITDA raised; census and member months unchanged.

Risks flagged

Net loss widening; GAAP profitability remains elusive despite operational improvements.

“Net loss $29.9M vs $11.1M; loss before income taxes $29.8M vs $11.1M.”

Dependence on government payors (Medicaid/Medicare); budget cuts could pressure rates.

“Risk factors include state and federal efforts to reduce healthcare spending, including Medicaid budget cuts.”

Labor shortages and competition could impact cost structure and growth.

“Risk factors mention labor shortages and labor competition.”
Read the original on SEC EDGAR ↗
3 Feb 20268-K · 2.02InnovAge reported strong Q2 FY2026 results: revenue +14.7% YoY, net income swing to $11.8M from -$13.5M, Adj. EBITDA $22.2M vs $5.9M, and raised FY2026 guidance for revenue and Adj. EBITDA.earningsopen

Figures in the filing · each found in the filing text

Total revenues · Q2-2026$240M+15% y/y
Net Income (Loss) · Q2-2026$12M-188% y/y
Adjusted EBITDA · Q2-2026$22M+277% y/y
Center-level Contribution Margin · Q2-2026$53M+43% y/y
Census · Q2-20268,010+7% y/y
Net Income (Loss) per share - basic and diluted · Q2-2026$0.08-180% y/y
Cash and cash equivalents · Q2-2026$83M
Short-term investments · Q2-2026$43M
Debt · Q2-2026$70M

Guidance

FY26 total revenues raised to $925-950M (prior not stated); FY26 Adjusted EBITDA raised to $70-75M (prior not stated); FY26 census unchanged at 7,900-8,100; FY26 total member months 92,900-95,700.

Raised FY2026 revenue and Adjusted EBITDA guidance reflecting strong operational momentum and confidence in continued growth.

Risks flagged

Dependence on government payors and regulatory risk.

“The dependence of our revenues upon a limited number of government payors, including the risk of sudden loss of any of our government contracts.” · word for word

Labor shortages and inflation could pressure costs.

“The impact on our business from ongoing macroeconomic related challenges, including labor shortages, labor competition, inflation, tariffs and trade disputes.” · word for word
Read the original on SEC EDGAR ↗
3 Feb 202610-QInnovAge reported Q2 FY2026 revenue of $239.7M (+14.8% YoY), swung to net income of $10.6M from a $13.2M loss, and expanded Adjusted EBITDA margin to 8.4%.earningsopen

Figures in the filing · each found in the filing text

Revenue · Q2-2026$240M+15% y/y
Revenue · 6M-2026$476M+15% y/y
Net Income · Q2-2026$11M
Net Income · 6M-2026$19M
Operating Cash Flow · 6M-2026$25M
Adjusted EBITDA · Q2-2026$22M
Adjusted EBITDA · 6M-2026$40M
Census · 2025-12-318,010+7% y/y
Total Member Months · 6M-202647,460+9% y/y
Center-level Contribution Margin · 6M-2026$104M+46% y/y

Risks flagged

Medicaid Funding Cuts (OBBBA)

“The OBBBA adopted in July 2025, mandates significant reductions in federal Medicaid spending, introduces new work requirements for Medicaid beneficiaries aged 19 to 64 and cost-sharing measures for certain Medicaid beneficiaries, and requires states to conduct bi-annual eligibility verifications of Medicaid enrollees in the expansion population.” · word for word

California Regulatory Moratorium

“Effective November 20, 2025, the California Department of Health Care Services (DHCS) paused PACE applications for all PACE organizations for a minimum of two years, or until otherwise notified.” · word for word

Labor Cost Inflation

“The healthcare sector continues to experience workforce shortages, particularly in geriatrics, primary care and direct care roles, as well as a complex set of challenges in hiring additional professionals, which continued through the second quarter of fiscal year 2026.” · word for word

Corrective Action Plan (CAP) in California

“On December 23, 2025, we received a formal Corrective Action Plan (CAP) from DHCS to remediate findings resulting from the San Bernardino medical review.” · word for word
Read the original on SEC EDGAR ↗
4 Nov 20258-K · 2.02InnovAge reported Q1 FY2026 revenue of $236.1M (+15.1% YoY), net income of $7.7M vs loss of $5.7M, and confirmed FY2026 guidance for revenue $900-950M and Adjusted EBITDA $56-65M.earningsopen

Figures in the filing · each found in the filing text

Total Revenues · Q1-2026$236M+15% y/y
Net Income (Loss) · Q1-2026$8M-234% y/y
Adjusted EBITDA · Q1-2026$18M+172% y/y
Center-level Contribution Margin · Q1-2026$51M+49% y/y
Census · Q1-20267,890+9% y/y
Cash and Cash Equivalents · Q1-2026$67M
Short-term Investments · Q1-2026$42M
Debt · Q1-2026$72M

Guidance

FY2026 Total revenues $900-950M; Adjusted EBITDA $56-65M; Census 7,900-8,100; Total Member Months 91,600-94,400

Confirmed FY2026 guidance; strong start to fiscal year with profitability improvement.

Risks flagged

Dependence on government payors; risk of budget cuts.

“Risk factors mention dependence on government payors and state/federal efforts to reduce healthcare spending.”

Labor shortages and inflation could impact costs.

“Risk factors include labor shortages, labor competition, inflation, tariffs and trade disputes.”
Read the original on SEC EDGAR ↗
4 Nov 202510-QNo material event; quarterly results show strong revenue growth and return to profitability.open

Figures in the filing · each found in the filing text

Census · Q1-20267,890+9% y/y
Total Member Months · Q1-202623,500+10% y/y
Center-level Contribution Margin · Q1-2026$51M+49% y/y
Center-level Contribution Margin as % of revenue · Q1-202621.8%
Adjusted EBITDA · Q1-2026$18M+172% y/y
Adjusted EBITDA Margin · Q1-20267.5%
Capitation Revenue · Q1-2026$236M+15% y/y
Revenue · Q1-2026$236M+15% y/y
Net Income (Loss) · Q1-2026$8M+234% y/y
Operating Cash Flow · Q1-2026$4M+152% y/y

Risks flagged

Medicaid Funding Cuts

“The OBBBA adopted in July 2025, mandates significant reductions in federal Medicaid spending, introduces new work requirements for Medicaid beneficiaries aged 19 to 64 and cost-sharing measures for certain Medicaid beneficiaries, and requires states to conduct bi-annual eligibility verifications of Medicaid enrollees in the expansion population.” · word for word

Regulatory Suspension of California De Novo Centers

“DHCS notified us that it was suspending its attestations in support of the planned de novo center in Downey and the recently acquired planned de novo center in Bakersfield.” · word for word

Labor Cost Pressure

“These labor market pressures have increased wage and benefit costs, and have also affected our staffing ability which could impact our enrollment capacity and services.” · word for word

Government Shutdown Delays

“Additionally, the federal government entered a partial shutdown effective October 1, 2025. While we have not experienced any direct impact to date, we may experience delays related to government agencies operating in this reduced capacity.” · word for word
Read the original on SEC EDGAR ↗

InnovAge Holding Corp. — questions

What did InnovAge Holding Corp. file recently?
10 SEC filings in the last 12 months. Latest: DEF 14A on 2026-10-22 — Annual proxy statement filed for shareholder vote on director elections, say-on-pay, and auditor ratification.

Every figure on this page comes from InnovAge Holding Corp.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.